TMPRSS2 and acute pancreatitis: Adopting this method, repurposing of the anticoagulant drug nafamostat (1, Figure 1) and the anti-acute pancreatitis camostat (2, Figure 1) showed that they can potentially inhibit TMPRSS2-dependent viral entry, and they underwent clinical trials as possible COVID-19 treatments [15,17,43,44,45].